Titre : | Directly Observed Antidepressant Medication Treatment and HIV Outcomes Among Homeless and Marginally Housed HIV-Positive Adults : A Randomized Controlled Trial. (2013) |
Auteurs : | TSAI (Alexander-C) : USA. Langley Porter Psychiatric Institute. University of California. San Francisco. ; David-R BANGSBERG ; Edwin-D CHARLEBOIS ; James-W DILLEY ; Gwendolyn-P HAMMER ; Dan-H KARASIC ; Andrew-R MOSS ; Kathy RAGLAND ; James-L SORENSEN ; Department of Psychiatry. San Francisco General Hospital. University of California. San Francisco. USA ; Epidemiology and Prevention Interventions Center. Division of Infectious Diseases. San Francisco General Hospital. University of California. San Francisco. USA |
Type de document : | Article |
Dans : | American journal of public health (vol. 103, n° 2, 2013) |
Pagination : | 308-315 |
Langues: | Anglais |
Mots-clés : | Sida ; Médicament antituberculeux ; Thérapeutique médicamenteuse ; Chimiothérapie ; Observance thérapeutique ; Antidépresseur ; Médicament ; VIH ; Evolution ; Pronostic ; Thérapeutique ; Sans domicile fixe ; Adulte ; Essai thérapeutique ; Randomisation ; Médicament psychotrope ; Virose ; Infection ; Rétrovirus ; Virus ; Homme ; Immunopathologie |
Résumé : | [BDSP. Notice produite par INIST-CNRS F7R0xH97. Diffusion soumise à autorisation]. Objectives. We assessed whether directly observed fluoxetine treatment reduced depression symptom severity and improved HIV outcomes among homeless and marginally housed HIV-positive adults in San Francisco, California, from 2002 to 2008. Methods. We conducted a nonblinded, randomized controlled trial of once-weekly fluoxetine, directly observed for 24 weeks, then self-administered for 12 weeks (n=137 persons with major or minor depressive disorder or dysthymia). Hamilton Depression Rating Scale score was the primary outcome. Response was a 50% reduction from baseline and remission a score below 8. Secondary measures were Beck Depression Inventory-II (BDI-II) score, antiretroviral uptake, antiretroviral adherence (measured by unannounced pill count), and HIV-1 RNA viral suppression ( |